Search

Your search keyword '"Kapur, Navin K."' showing total 47 results
Start Over Author "Kapur, Navin K." Journal journal of cardiac failure
47 results on '"Kapur, Navin K."'

2. Outcomes of Patients Transferred to Tertiary Care Centers for Treatment of Cardiogenic Shock: A Cardiogenic Shock Working Group Analysis

Author

GARAN, A. RESHAD, KATARIA, RACHNA, LI, BORUI, SINHA, SHASHANK, KANWAR, MANREET K., HERNANDEZ-MONTFORT, JAIME, LI, SONG, TON, VAN-KHUE, BLUMER, VANESSA, GRANDIN, E. WILSON, HARWANI, NEIL, ZAZZALI, PETER, WALEC, KAROL D., HICKEY, GAVIN, ABRAHAM, JACOB, MAHR, CLAUDIUS, NATHAN, SANDEEP, VOROVICH, ESTHER, GUGLIN, MAYA, HALL, SHELLEY, KHALIFE, WISSAM, SANGAL, PAAVNI, ZHANG, YIJING, KIM, JU H., SCHWARTZMAN, ANDREW, VISHNEVSKY, ALEC, BURKHOFF, DANIEL, and KAPUR, NAVIN K.

Published
2024
Full Text
View/download PDF

3. Pulmonary Artery Catheter Use and Risk of In-hospital Death in Heart Failure Cardiogenic Shock

Author

KANWAR, MANREET K., BLUMER, VANESSA, ZHANG, YIJING, SINHA, SHASHANK S., GARAN, ARTHUR R., HERNANDEZ-MONTFORT, JAIME, KHALIF, ADNAN, HICKEY, GAVIN W., ABRAHAM, JACOB, MAHR, CLAUDIUS, LI, BORUI, SANGAL, PAAVNI, WALEC, KAROL D., ZAZZALI, PETER, KATARIA, RACHNA, PAHUJA, MOHIT, TON, VAN-KHUE, HARWANI, NEIL M., WENCKER, DETLEF, NATHAN, SANDEEP, VOROVICH, ESTHER, HALL, SHELLEY, KHALIFE, WISSAM, LI, SONG, SCHWARTZMAN, ANDREW, KIM, JU, VISHNEVSKY, OLEG ALEC, TRINQUART, LUDOVIC, BURKHOFF, DANIEL, and KAPUR, NAVIN K.

Published
2023
Full Text
View/download PDF

5. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion.

Author

NATOV, PETER S., IVEY-MIRANDA, JUAN B., COX, ZACHARY L., RAO, VEENA S., BUTLER, JAVED, KONSTAM, MARVIN A., KIERNAN, MICHAEL S., KAPUR, NAVIN K., and TESTANI, JEFFREY M.

Abstract

• The ATHENA-HF clinical trial did not find additional decongestive benefit of spironolactone 100 mg/day for 96 hours in acute heart failure. • We performed a post hoc analysis of whether this spironolactone dosage had any pharmacodynamic effects. • We found that increased spironolactone dosing limited potassium losses in acute heart failure treatment and reduced the need for potassium replacement. • However, patients with acute heart failure and lower serum potassium levels did not experience greater decongestion with this intervention. The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) clinical trial found no improvements in natriuretic peptide levels or clinical congestion when spironolactone 100 mg/day for 96 hours was used in addition to usual treatment for acute heart failure. We performed a post hoc analysis of ATHENA-HF to determine whether spironolactone treatment induced any detectable pharmacodynamic effects and whether patients with potentially greater aldosterone activity experienced additional decongestion. Trial subjects previously treated with spironolactone were excluded. We first examined for changes in renal potassium handling. Using the baseline serum potassium level as a surrogate marker of spironolactone activity, we then divided each treatment arm into tertiles of baseline serum potassium and explored for differences in laboratory and clinical congestion outcomes. Among spironolactone-naïve patients, the change in serum potassium did not differ after 24 hours or 48 hours but was significantly greater with spironolactone treatment compared to placebo at 72 hours (0.23 ± 0.55 vs 0.03 ± 0.60 mEq/L; P = 0.042) and 96 hours (0.32 ± 0.51 vs 0.13 ± 0.72 mEq/L; P = 0.046). Potassium supplementation was similar at treatment start and at 24 hours, but spironolactone-treated patients required substantially less potassium replacement at 48 hours (24% vs 36%; P = 0.048), 72 hours (21% vs 37%; P = 0.013), and 96 hours (11% vs 38%; P < 0.001). When the treatment arms were divided into tertiles of baseline serum potassium, there were no differences in the 96-hour log N-terminal pro-B-type natriuretic peptide levels, net fluid loss, urine output, or dyspnea relief in any of the potassium groups, with no effect modification by treatment exposure. Spironolactone 100 mg/day for 96 hours in patients receiving intravenous loop diuresis for acute heart failure has no clear added decongestive ability but does meaningfully limit potassium wasting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Right Ventricular Dysfunction Is Common and Identifies Patients at Risk of Dying in Cardiogenic Shock

Author

Jain, Pankaj, THAYER, Katherine L., ABRAHAM, Jacob, EVERETT, Kay D., PAHUJA, Mohit, WHITEHEAD, Evan H., SCHWARTZ, Benjamin P., LALA, Anuradha, SINHA, Shashank S., KANWAR, Manreet K., GARAN, A Reshad, HERNANDEZ-MONFORT, Jaime A, MAHR, Claudius, VOROVICH, Esther, WENCKER, Detlef, MCCABE, James M., JONES, Tara, GOUD, Maithri, BACA, Paulina, HARWANI, Neil, BURKHOFF, Daniel, and KAPUR, NAVIN K.

Published
2021
Full Text
View/download PDF

10. Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock

Author

VALLABHAJOSYULA, SARASCHANDRA, FAUGNO, ANTHONY J., LI, BORUI, JOHN, KEVIN, KONG, QIUYUE, SINHA, SHASHANK S., HERNANDEZ-MONTFORT, JAIME, KANWAR, MANREET K., ABRAHAM, JACOB, BLUMER, VANESSA, FARR, MARYJANE, FRIED, JUSTIN, GARAN, ARTHUR R., HALL, SHELLEY, HICKEY, GAVIN W., KATARIA, RACHNA, KIM, JU, LI, SONG, MAHR, CLAUDIUS, NATHAN, SANDEEP, PAHUJA, MOHIT, SANGAL, PAAVNI, SCHWARTZMAN, ANDREW, TON, VAN-KHUE, VISHNEVSKY, OLEG A., VOROVICH, ESTHER, WALEC, KAROL D., ZAZZALI, PETER, ZWECK, ELRIC, BURKHOFF, DANIEL, and KAPUR, NAVIN K.

Published
2024
Full Text
View/download PDF

11. Trends in the Incidence of In-Hospital Mortality, Cardiogenic Shock, and Utilization of Mechanical Circulatory Support Devices in Myocarditis (Analysis of National Inpatient Sample Data, 2005–2014)

Author

Pahuja, MOHIT, ADEGBALA, OLUWOLE, MISHRA, TUSHAR, AKINTOYE, EMMANUEL, CHEHAB, OMAR, MONY, SHRUTI, SINGH, MANMOHAN, ANDO, TOMO, ABUBAKER, HOSSAM, YASSIN, AHMED, SUBAHI, AHMED, SHOKR, MOHAMED, RANKA, SAGAR, BRIASOULIS, ALEXANDROS, KAPUR, Navin K., BURKHOFF, DANIEL, and AFONSO, LUIS

Published
2019
Full Text
View/download PDF

12. Interventional Heart Failure: Current State of the Field

Author

Villela, Miguel Alvarez, primary, Liu, Stephen, additional, Yin, Michael, additional, Esposito, Michele L, additional, Aghili, Nima, additional, Mustehsan, Muhammad H, additional, Larson, Ian, additional, Diakos, Nikolaos A, additional, and Kapur, Navin K, additional

Published
2023
Full Text
View/download PDF

13. Outcomes of Patients Transferred to Tertiary Care Centers for Treatment of Cardiogenic Shock: A Cardiogenic Shock Working Group Analysis

Author

Garan, A. Reshad, primary, Kataria, Rachna, additional, Li, Borui, additional, Sinha, Shashank, additional, Kanwar, Manreet K., additional, Hernandez-Montfort, Jaime, additional, Li, Song, additional, Ton, Van-Khue, additional, Blumer, Vanessa, additional, Grandin, E. Wilson, additional, Harwani, Neil, additional, Zazzali, Peter, additional, Walec, Karol D., additional, Hickey, Gavin, additional, Abraham, Jacob, additional, Mahr, Claudius, additional, Nathan, Sandeep, additional, Vorovich, Esther, additional, Guglin, Maya, additional, Hall, Shelley, additional, Khalife, Wissam, additional, Sangal, Paavni, additional, Zhang, Yijing, additional, Kim, Ju H., additional, Schwartzman, Andrew, additional, Vishnevsky, Alec, additional, Burkhoff, Daniel, additional, and Kapur, Navin K., additional

Published
2023
Full Text
View/download PDF

19. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology–Association Canadienne de Cardiologie d'intervention)

Author

Rihal, Charanjit S., Naidu, Srihari S., Givertz, Michael M., Szeto, Wilson Y., Burke, James A., Kapur, Navin K., Kern, Morton, Garratt, Kirk N., Goldstein, James A., Dimas, Vivian, and Tu, Thomas

Published
2015
Full Text
View/download PDF

25. Transitions In Hemometabolic Related Cardiogenic Shock

Author

Hernandez-Montfort, Jaime, primary, Thayer, Katherine L., additional, Schwartz, Benjamin, additional, Garan, Arthur R., additional, Mahr, Claudius, additional, Sihna, Shashank, additional, Burkhoff, Daniel, additional, and Kapur, Navin K., additional

Published
2020
Full Text
View/download PDF

27. HFSA and AAHFN Joint Position Statement: Advocating for a Full Scope of Nursing Practice and Leadership in Heart Failure

Author

Lee, Christopher S., Greenberg, Barry H., Laramee, Ann S., Ammon, Susan E., Prasun, Marilyn, Galvao, Marie, Doering, Lynn V., Sherman, M. Eugene, Stevenson, Lynne Warner, Gregory, Douglas D., Heidenreich, Paul A., Kapur, Navin K., O’Connell, John B., Taylor, Anne L., Hill, Joseph A., Baas, Linda, Gibbs, Ashley, Rasmusson, Kismet, Lewis, Connie, Kirkwood, Peggy, Reigle, Juanita, Rathman, Lisa, and Bither, Cynthia

Published
2012
Full Text
View/download PDF

32. Right Ventricular Dysfunction in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Hemodynamic Analysis of the SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK (SHOCK) Trial and Registry

Author

Lala, Anuradha, primary, Guo, Yu, additional, Xu, Jinfeng, additional, Karas, Richard, additional, Katz, Stuart D., additional, Josephy, Noam, additional, Burkhoff, Daniel, additional, and Kapur, Navin K., additional

Published
2016
Full Text
View/download PDF

34. Acute Hemodynamic Effects of Large Capacity Intra-Aortic Balloon Counterpulsation Pumps in Patients with Advanced Heart Failure

Author

Annamalai, Shiva, primary, Buitten, Lyanne, additional, Esposito, Michele, additional, Kang, Sandra, additional, Mackey, Emily, additional, O'Kelly, Ryan, additional, Kimmelstiel, Carey, additional, DeNofrio, David, additional, Kiernan, Michael, additional, Vest, Amanda, additional, Patel, Ayan, additional, and Kapur, Navin K., additional

Published
2016
Full Text
View/download PDF

42. Signaling Via Calcineurin and the Canonical Transient Receptor Protein-6 Channel (TRPC6) Requires Endoglin in Right Ventricle Pressure Overload

Author

Kapur, Navin K., primary, Qiao, Xiaoying, additional, Paruchuri, Vikram, additional, Mackey, Emily E., additional, Daly, Gerard, additional, Ughreja, Keshan, additional, Levine, Jonathan, additional, Aronovitz, Mark J., additional, Jin, Hongwei, additional, Galper, Jonas B., additional, and Karas, Richard H., additional

Published
2013
Full Text
View/download PDF

47. Association of Hemometabolic Trajectory and Mortality: Insights From the Cardiogenic Shock Working Group Registry.

Author

Khalife W, Kanwar MK, Abraham J, Li S, John K, Sinha SS, Zweck E, Li B, Garan AR, Hernandez-Montfort J, Zhang Y, Ton VK, Guglin M, Kataria R, Hickey GW, Vallabhajosyula S, Kong C, Farr M, Fried J, Hall S, Harwani NM, Mahr C, Nathan S, Sangal P, Schwartzman A, Bhimaraj A, Kim JU, Vishnevsky AA, Vorovich E, Walec KD, Zazzali P, Albaeni A, Burkhoff D, and Kapur NK

Subjects
Humans, Male, Female, Middle Aged, Aged, Shock, Cardiogenic mortality, Shock, Cardiogenic physiopathology, Shock, Cardiogenic therapy, Registries, Hospital Mortality trends, Hemodynamics physiology
Abstract

Cardiogenic shock (CS) is a hemodynamic syndrome that can progress to systemic metabolic derangements and end-organ dysfunction. Prior studies have reported hemodynamic parameters at the time of admission to be associated with mortality but hemodynamic trajectories in CS have not been well described. We studied the association between hemodynamic profiles and their trajectories and in-hospital mortality in patients with CS due to heart failure (HF-CS) and acute myocardial infarction (MI-CS). Using data from the large multicenter Cardiogenic Shock Working Group (CSWG) registry, we analyzed hemodynamic data obtained at the time of pulmonary artery catheter (PAC) insertion (dataset at baseline) and at PAC removal or death (dataset at final time point). Univariable regression analyses for prediction of in-hospital mortality were conducted for baseline and final hemodynamic values, as well as the interval change (delta-P). Data was further analyzed based on CS etiology and survival status. A total of 2260 patients with PAC data were included (70% male, age 61 ± 14 years, 61% HF-CS, 27% MI-CS). In-hospital mortality was higher in the MI-CS group (40.1%) compared with HF-CS (22.4%, P < .01). In the HF-CS cohort, survivors exhibited lower right atrial pressure (RAP), pulmonary artery pressure (PAP), cardiac output/index (CO/CI), lactate, and higher blood pressure (BP) than nonsurvivors at baseline. In this cohort, during hospitalization, improvement in metabolic (aspartate transaminase, lactate), BP, hemodynamic (RAP, pulmonary artery pulsatility index [PAPi], pulmonary artery compliance for right-sided profile and CO/CI for left-sided profile), had association with survival. In the MI-CS cohort, a lower systolic BP and higher PAP at baseline were associated with odds of death. Improvement in metabolic (lactate), BP, hemodynamic (RAP, PAPi for right-sided profile and CO/CI for left-sided profile) were associated with survival. In a large contemporary CS registry, hemodynamic trajectories had a strong association with short-term outcomes in both cohorts. These findings suggest the clinical importance of timing and monitoring hemodynamic trajectories to tailor management in patients with CS., (Copyright © 2024 Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results